X-Health.show’s Post

A big thank you to Aleksandra Jani, MCIM for inviting our CEO Danielle Ralic to join the X-Health.show to share our work at Ancora.ai. Listen to the podcast to learn more about how searching for #clinicaltrials today is nearly impossible and how tech can change that to unlock access to trials. Test it out yourself by first searching for #cancer trials on www.clinicaltrials.gov, and then searching for trials on https://www.ancora.ai. You'll see how tech, specifically #AI, can help make searching through complex information much easier and more accessible. And remember, clinical trials can offer treatment options and it's important to know all your options. A 5 minute search on www.ancora.ai could help you find the treatment option that makes all the difference.

AI-Driven Breakthroughs in Oncology: Immunai and #AstraZeneca Join Forces!! Immunai, a leading AI and biotech company based in New York, has announced a multi-year collaboration with AstraZeneca to revolutionize oncology clinical trials. Leveraging Immunai’s advanced immune system mapping technology, this partnership aims to enhance decision-making processes in drug development. Key Features: 1. AMICA™ Immune Cell Atlas: Immunai’s proprietary platform maps the human immune system, offering precise insights into immune responses. 2. Immunodynamics Engine (IDE)™: AI-powered model that enhances clinical decision-making by identifying patient responders and mechanisms of action. 3. $18 Million Investment: AstraZeneca will invest $18 million in the initial phase, with an option to expand the collaboration. 4. Oncology Focus: Initial trials will optimize dosage selection, patient response, and biomarker identification for cancer treatments. 5. Ongoing Partnership: Building on their successful collaboration since 2022, this new phase deepens AstraZeneca's use of AI in clinical research. Image Source: immunai.com/ Stay ahead with the latest insights and breakthroughs in AI-driven healthcare. Subscribe now for free to read our upcoming newsletter- https://lnkd.in/drMdAFND #hearthealth #aihealthcare #healthcare #ainews #aiinmedicine #heartdisease #aibreakthroughs #aiinnovation #aidevelopments #cancercare #cancer #diabetes #breastcancer #astrazeneca #oncology

AI-Driven Breakthroughs in Oncology: Immunai and #AstraZeneca Join Forces!! Immunai, a leading AI and biotech company based in New York, has announced a multi-year collaboration with AstraZeneca to revolutionize oncology clinical trials. Leveraging Immunai’s advanced immune system mapping technology, this partnership aims to enhance decision-making processes in drug development. Key Features: 1. AMICA™ Immune Cell Atlas: Immunai’s proprietary platform maps the human immune system, offering precise insights into immune responses. 2. Immunodynamics Engine (IDE)™: AI-powered model that enhances clinical decision-making by identifying patient responders and mechanisms of action. 3. $18 Million Investment: AstraZeneca will invest $18 million in the initial phase, with an option to expand the collaboration. 4. Oncology Focus: Initial trials will optimize dosage selection, patient response, and biomarker identification for cancer treatments. 5. Ongoing Partnership: Building on their successful collaboration since 2022, this new phase deepens AstraZeneca's use of AI in clinical research. Image Source: immunai.com/ Stay ahead with the latest insights and breakthroughs in AI-driven healthcare. Subscribe now for free to read our upcoming newsletter- https://lnkd.in/drMdAFND #hearthealth #aihealthcare #healthcare #ainews #aiinmedicine #heartdisease #aibreakthroughs #aiinnovation #aidevelopments #cancercare #cancer #diabetes #breastcancer #astrazeneca #oncology

Exciting advancements in oncology continue to revolutionize patient care worldwide, but with progress comes challenges. The latest insights from #IQVIA shed light on the complex landscape of cancer treatment, from emerging #research to disparities in patient #access. As we navigate these trends, it's crucial for stakeholders to come #together for meaningful discussion and action. 💛 Let's harness the power of innovation to ensure equitable access and sustainable healthcare solutions. #OncologyInnovation #Healthcare IQVIA Global Market Insights Smartway Pharmaceuticals

#ICYMI: Popular Episodes of "Rx for Biotech" Featuring Emerging Radiopharmaceutical Companies! 🎧 Catch Up on the Latest Episodes of #RxforBiotech! 🎧 The radiopharmaceutical market is booming, and we’ve got two incredible episodes you don’t want to miss, highlighting some of the most innovative companies in the field. Episode 1: Inside Ratio Therapeutics Join us as we sit down with the brilliant minds behind Ratio Therapeutics. Co-Founders, Jack Hoppin, and John Babich, share their mission to develop best-in-class radiopharmaceuticals for cancer treatment. Learn about their groundbreaking research and what drives their passion for innovation in this rapidly evolving industry. Episode 2: Convergent Therapeutics' Vision In our second spotlight, Philip Kantoff, CEO and Co-Founder of Convergent Therapeutics, Inc., delves into the company’s pioneering efforts to develop next-generation PSMA targeting radiopharmaceuticals for prostate cancer treatment. Discover the cutting-edge advancements and the future of prostate cancer therapies straight from an industry leader. 🔗 Tune in Now to hear from the experts who are shaping the future of cancer treatment with radiopharmaceuticals. Links to both episodes are in comments below ⬇ 👉 Don’t miss out on these insightful discussions and stay updated with the latest trends and breakthroughs in biotech! #RxForBiotech #Radiopharmaceuticals #CancerTreatment #BiotechInnovation #RatioTherapeutics #ConvergentTherapeutics #PodcastEpisodes #CancerResearch #ProstateCancer #PSMATargeting #RadioligandTherapy #NucMed #Podcast

🔬💊 Attention pharmaceutical and biotech companies! Are you truly understanding the needs of cancer patients in today's complex medical landscape? Drug makers face numerous obstacles in reaching the patients crucial for developing life-extending and life-saving treatments. Meanwhile, patient trust in some companies wavers. Are their concerns justified? Perhaps. With fierce competition for patient populations and the targeting of rare conditions, patients can feel lost in the shuffle. But at Leal Health, we're changing the game. We recognize that patients deserve more than impersonal online searches and rushed doctor visits. That's why we provide every patient with a dedicated point of contact—an expert with intimate knowledge of their specific cancer type and treatment options. Would you prefer approved therapies first? We've got you covered! Don't want to undergo chemotherapy? Let's explore your options together. Feeling like you've exhausted every avenue? We're here for the entire journey, supporting you every step of the way. In a world where oncologists are limited to mere minutes per visit, we offer patients the personalized support and guidance they deserve. No more sifting through endless articles or fearing the unknown. We empower patients to make informed decisions about their treatment journey, regardless of the sponsor. You need help finding resources during your treatment? We've got something for that too! Oncology treatment is tough, but together, we can make a difference. Join us at Leal Health, where we provide hope, support, knowledge, and empowerment to cancer patients every step of the way. Let's work together to revolutionize cancer care! 💪🩺 #LealHealth #CancerCare #PatientEmpowerment #ClinicalTrials #LealImpact #freeforpatients #oncology

Exciting news in the fight against breast cancer! Mika Health, a digital therapeutics platform, has partnered with pharmaceutical giants AstraZeneca and Daiichi Sankyo US to launch UNITE - an initiative aimed at improving the treatment experience for women with breast cancer in Switzerland. The UNITE program will provide customized access and support through the Mika Health app, initially rolling out to breast cancer patients in German-speaking Switzerland. Patients will receive personalized coaching, AI-enabled recommendations, and daily symptom monitoring, all integrated with their pharmaceutical therapy. This innovative collaboration combines evidence-based digital support with cutting-edge drug research, offering a holistic approach to cancer care. By empowering patients with tailored resources and tools, UNITE aims to enhance understanding, increase control, and improve both physical and mental well-being throughout the treatment journey. A significant step towards better cancer treatment experiences and survival rates, this partnership exemplifies the power of technology and collaboration in transforming healthcare. Stay tuned as UNITE expands to other regions of Switzerland and potentially other disease areas. https://lnkd.in/e4fgW5_h 📰 Stay ahead of the curve by following Practical Patient Care on LinkedIn for more industry news and insights. You can also access our latest edition here: https://lnkd.in/guUBWkRE #PracticalPatientCare #HealthTech #Collaboration

Mika Health partners with pharma giants for women’s oncology initiative - MobiHealthNews Title: Mika Health partners with pharma giants for women's oncology initiative #Partnership with Pharma Giants Mika Health has announced a strategic partnership with leading pharmaceutical companies to launch a women's oncology initiative. The collaboration aims to improve access to specialized care and treatment options for women with cancer. #Focus on Women's Health The initiative will focus on addressing the unique healthcare needs of women with cancer, including early detection, personalized treatment plans, and ongoing support services. Mika Health is committed to advancing women's health outcomes through innovative technology solutions. #Empowering Patients By partnering with pharma giants, Mika Health aims to empower patients with valuable resources and information to make informed decisions about their care. The initiative will leverage ai.mediformatica.com #cancer #health #patients #acce #digital #oncology #partners #partnership #provide #astrazeneca #digitaltherapeutics #medication #digitalhealth #healthit #healthtech #healthcaretechnology @MediFormatica (https://buff.ly/3RB7kmu)

Calling All Companies Making a Difference in Breast Cancer Awareness! Are you passionate about empowering breast cancer groups, survivors, and medical leaders? We've tailored our partnership packages with you in mind! Educational Resources: Help educate and empower by sharing valuable insights, knowledge, and resources. Pharmaceutical & Oncology: Showcase groundbreaking treatments and innovations shaping the future of breast cancer care. Genetic Testing & Education: Provide essential information on genetic testing and personalized treatment options. Recovery Products & Services: Support survivors on their journey to recovery with specialized products and services. Survival Support Groups: Connect with and offer support to those navigating the challenges of breast cancer. Clinical Trial Services: Drive advancements in breast cancer research by promoting clinical trial opportunities. Detection Medical Devices & Services: Highlight cutting-edge technologies and services improving early detection rates. Telehealth Services: Make healthcare more accessible and convenient for patients through telehealth solutions. Join us in making a real impact in the fight against breast cancer. Let's partner together to educate, support, and empower those affected by this disease. Contact us today to explore partnership opportunities tailored to your brand! #BreastCancerAwareness #PartnershipOpportunities #EmpowerTogether

𝐊𝐢𝐧𝐞𝐭𝐚 𝐈𝐧𝐜. 𝐑𝐞𝐨𝐩𝐞𝐧𝐬 𝐄𝐧𝐫𝐨𝐥𝐥𝐦𝐞𝐧𝐭 𝐟𝐨𝐫 𝐕𝐈𝐒𝐓𝐀-101 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐓𝐫𝐢𝐚𝐥 𝐟𝐨𝐫 𝐀𝐝𝐯𝐚𝐧𝐜𝐞𝐝 𝐒𝐨𝐥𝐢𝐝 𝐓𝐮𝐦𝐨𝐫 𝐂𝐚𝐧𝐜𝐞𝐫 TuHURA Biosciences is making strides in the fight against cancer, joining forces with Kineta, Inc. to reopen patient enrollment in the VISTA-101 Phase 1/2 clinical trial. Under an Exclusivity and Right of First Offer Agreement, this collaboration centers around Kineta’s promising VISTA-blocking antibody, KVA12123. 𝐀𝐛𝐨𝐮𝐭 𝐊𝐕𝐀12123: KVA12123 is an innovative immunotherapy designed to block VISTA, a checkpoint that suppresses T cell function in solid tumors. The therapy has shown encouraging results, with partial responses and stable disease in combination with Merck’s KEYTRUDA® (pembrolizumab), and durable stable disease in monotherapy. Notably, KVA12123 has demonstrated a strong safety profile, with no dose-limiting toxicities or cytokine release syndrome observed to date. With the expected completion of the Phase 1 trial portion by the end of 2024, this partnership could pave the way for new, effective cancer treatments. Stay tuned for more updates as these companies push the boundaries of oncology advancement. #CancerTreatment #ImmunoOncology #ClinicalTrials #BiotechInnovation #Healthcare #OncologyResearch